

Halaven Approval Status Worldwide (Country/ Region)

March, 2023

Breast Cancer 3rd line

Algeria	May-2019	Egypt	Dec-2019	Lebanon	May-2013	Qatar	Aug-2017
Argentina	Jun-2019	Estonia	Mar-2011	Liechtenstein	Mar-2011	Romania	Mar-2011
Australia	Aug-2012	Finland	Mar-2011	Lithuania	Mar-2011	Russia	Jul-2012
Austria	Mar-2011	France	Mar-2011	Luxembourg	Mar-2011	Saudi Arabia	Nov-2014
Bahrain	Jun-2016	Germany	Mar-2011	Macau	Jun-2012	Serbia	Aug-2013
Belgium	Mar-2011	Greece	Mar-2011	Malaysia	Sep-2012	Singapore	Feb-2011
Bosnia and Herzegovina	Jul-2013	Guatemala	Nov-2020	Malta	Mar-2011	Slovakia	Mar-2011
Brazil	May-2013	Hong Kong	Dec-2012	Mexico	Aug-2014	Slovenia	Mar-2011
Brunei	Dec-2018	Hungary	Mar-2011	Morocco	Dec-2014	South Africa	Jul-2016
Bulgaria	Mar-2011	Iceland	Mar-2011	Myanmar	Dec-2013	South Korea	Aug-2012
Cambodia	Oct-2017	India	Apr-2013	Netherlands	Mar-2011	Spain	Mar-2011
Canada	Dec-2011	Indonesia	Dec-2015	Norway	Mar-2011	Sri Lanka	Jan-2019
China	Jul-2019	Ireland	Mar-2011	Oman	Nov-2016	Sweden	Mar-2011
Chile	Sep-2019	Israel	May-2012	Pakistan	Jan-2019	Switzerland	May-2011
Colombia	Nov-2021	Italy	Mar-2011	Panama	May-2020	Taiwan	Aug-2013
Croatia	Jun-2012	Japan	Apr-2011	Paraguay	Jan-2022	Thailand	Dec-2012
Cyprus	Mar-2011	Jordan	May-2014	Peru	Jun-2019	UAE	Jan-2015
Czech Republic	Mar-2011	Kuwait	Oct-2012	Philippines	Mar-2013	UK	Mar-2011
Denmark	Mar-2011	Laos	Sep-2013	Poland	Mar-2011	US	Nov-2010
Ecuador	Aug-2020	Latvia	Mar-2011	Portugal	Mar-2011	Vietnam	Jul-2019

Note: The purpose of this document is to demonstrate that Eisai seeks to expand access to its products for patients in the world. Specific indication may vary in each country/region. Approval does not guarantee product availability.

Halaven Approval Status Worldwide (Country/ Region)

March, 2023

Breast Cancer, 2nd line

Argentina	Jun-2019	Finland	Jun-2014	Macau	Apr-2015	Saudi Arabia	Jan-2019
Australia	Nov-2015	France	Jun-2014	Malaysia	May-2018	Serbia	Feb-2018
Austria	Jun-2014	Germany	Jun-2014	Malta	Jun-2014	Slovakia	Jun-2014
Bahrain	Nov-2019	Greece	Jun-2014	Mexico	Mar-2018	Slovenia	Jun-2014
Bangladesh	Jul-2019	Guatemala	Nov-2020	Morocco	Dec-2014	South Africa	May-2019
Belgium	Jun-2014	Hong Kong	Oct-2014	Myanmar	Oct-2015	South Korea	Dec-2014
Bosnia and Herzegovina	Sep-2015	Hungary	Jun-2014	Namibia	Aug-2018	Spain	Jun-2014
Botswana	Aug-2021	Iceland	Jun-2014	Netherlands	Jun-2014	Sri Lanka	Jan-2019
Brazil	Sep-2018	India	Feb-2015	Norway	Jun-2014	Sweden	Jun-2014
Bulgaria	Jun-2014	Ireland	Jun-2014	Oman	Sep-2020	Switzerland	Jul-2014
Cambodia	Oct-2017	Israel	Nov-2014	Pakistan	Jan-2019	Thailand	Aug-2014
Chile	Sep-2019	Italy	Jun-2014	Panama	May-2020	UAE	Nov-2018
Costa Rica	Jun-2021	Jordan	Oct-2020	Paraguay	Jan-2022	UK	Jun-2014
Croatia	Jun-2014	Kazakhstan	Mar-2022	Peru	Jun-2019	Uruguay	Jan-2023
Cyprus	Jun-2014	Kuwait	Sep-2018	Philippines	Sep-2014	Vietnam	Jul-2019
Czech Republic	Jun-2014	Latvia	Jun-2014	Poland	Jun-2014	Zambia	Feb-2021
Denmark	Jun-2014	Lebanon	Feb-2018	Portugal	Jun-2014	Zimbabwe	Jan-2021
Ecuador	Aug-2020	Liechtenstein	Jun-2014	Qatar	Nov-2021		
Egypt	Dec-2019	Lithuania	Jun-2014	Romania	Jun-2014		
Estonia	Jun-2014	Luxembourg	Jun-2014	Russia	Nov-2014		

In Japan, Halaven® is approved for the treatment of inoperable and recurrent breast cancer.

Note: The purpose of this document is to demonstrate that Eisai seeks to expand access to its products for patients in the world. Specific indication may vary in each country/region. Approval does not guarantee product availability.

Halaven Approval Status Worldwide (Country/ Region)

March, 2023

Soft Tissue Sarcoma

Argentina	Jun-2019	Egypt	Dec-2019	Liechtenstein	May-2016	Qatar	Nov-2021
Australia	Nov-2016	Estonia	May-2016	Lithuania	May-2016	Romania	May-2016
Austria	May-2016	Finland	May-2016	Luxembourg	May-2016	Russia	Jun-2016
Bahrain	Nov-2019	France	May-2016	Macau	Jun-2017	Saudi Arabia	Jan-2019
Bangladesh	Jul-2019	Germany	May-2016	Malaysia	May-2018	Serbia	Apr-2019
Belgium	May-2016	Greece	May-2016	Malta	May-2016	Singapore	Mar-2017
Bosnia and Herzegovina	Feb-2018	Guatemala	Nov-2020	Mexico	Mar-2018	Slovakia	May-2016
Botswana	Aug-2021	Hong Kong	Feb-2017	Morocco	May-2018	Slovenia	May-2016
Brazil	Sep-2018	Hungary	May-2016	Myanmar	Oct-2018	South Africa	May-2019
Bulgaria	May-2016	Iceland	May-2016	Namibia	Aug-2018	South Korea	Jan-2017
Cambodia	Mar-2020	India	Oct-2016	Netherlands	May-2016	Spain	May-2016
Canada	Aug-2017	Indonesia	Jun-2018	Norway	May-2016	Sri Lanka	Jan-2019
Chile	Sep-2019	Ireland	May-2016	Oman	Sep-2020	Sweden	May-2016
Colombia	Nov-2021	Israel	Oct-2016	Pakistan	Jan-2019	Switzerland	Dec-2016
Costa Rica	Jun-2021	Italy	May-2016	Panama	May-2020	Taiwan	Nov-2016
Croatia	May-2016	Japan	Feb-2016	Paraguay	Jan-2022	Thailand	Sep-2017
Cyprus	May-2016	Jordan	Oct-2020	Peru	Jun-2019	UAE	Nov-2018
Czech Republic	May-2016	Kuwait	Sep-2018	Philippines	May-2016	UK	May-2016
Denmark	May-2016	Latvia	May-2016	Poland	May-2016	Uruguay	Jan-2023
Ecuador	Aug-2020	Lebanon	Feb-2018	Portugal	May-2016	US	Jan-2016

Note: The purpose of this document is to demonstrate that Eisai seeks to expand access to its products for patients in the world. Specific indication may vary in each country/region. Approval does not guarantee product availability.

Halaven Approval Status Worldwide (Country/ Region)

March, 2023

Soft Tissue Sarcoma

Zambia	Feb-2021
Zimbabwe	Jan-2021

Note: The purpose of this document is to demonstrate that Eisai seeks to expand access to its products for patients in the world. Specific indication may vary in each country/region. Approval does not guarantee product availability.